TY  - JOUR

T1  - 1.5-year posttreatment follow-up of radium-223 dichloride (Ra-223) safety in patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases from the phase 3 ALSYMPCA study

JO  - ONCOLOGY RESEARCH AND TREATMENT

PY  - 2014/10/01

AU  - Kuczyk M

AU  - Parker C

AU  - Vogelzang N

AU  - Sartor O

AU  - Bottomley D

AU  - Coleman R

AU  - Skjorestad I

AU  - Whaba M

AU  - Nilsson S

ED  - 

VL  - 37

SP  - 178

EP  - 178

Y2  - 2025/10/10

ER  -